Request a FREE Sample of our FcRn Binding Kit!Request a FREE Sample of our FcRn Binding Kit!
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
PAE-C5148 | SARS-CoV-2 | SARS-CoV-2 (COVID-19) Papain-like Protease Protein, His Tag (active enzyme) |
|
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Atilotrelvir/Ritonavir | Approved | Fujian Guangsheng Zhonglin Biotechnology Co Ltd | 泰中定 | Mainland China | Coronavirus Disease 2019 (COVID-19) | Fujian Guangsheng Zhonglin Biotechnology Co Ltd | 2023-11-23 | Coronavirus Disease 2019 (COVID-19) | Details | |
Simnotrelvir | SIM-0417; SSD-8432; VV-934 | Approved | Jiangsu Simcere Pharmaceutical Co Ltd | Mainland China | Coronavirus Disease 2019 (COVID-19) | Jiangsu Simcere Pharmaceutical Co Ltd | 2023-01-28 | Coronavirus Disease 2019 (COVID-19) | Details | |
Leritrelvir | RAY-1216; [14C]RAY1216; [14C]-RAY-1216 | Approved | Guangdong Raynovent Biotech Co Ltd | 乐睿灵 | Mainland China | Coronavirus Disease 2019 (COVID-19) | Guangdong Raynovent Biotech Co Ltd | 2023-03-23 | Coronavirus Disease 2019 (COVID-19); Acute Kidney Injury; Hepatic Insufficiency | Details |
Simnotrelvir/Ritonavir | SIM-0417/Ritonavir; SSD-8432 / Ritonavir; SIM-0417 / Ritonavir; VV934 / Ritonavir | Approved | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Jiangsu Simcere Pharmaceutical Co Ltd, Wuhan Institute Of Virology, Chinese Academy Of Sciences | 先诺欣 | Mainland China | Coronavirus Disease 2019 (COVID-19) | Jiangsu Simcere Pharmaceutical Co Ltd | 2023-01-28 | Coronavirus Disease 2019 (COVID-19); Kidney Diseases; Hepatic Insufficiency | Details |
Ensitrelvir Fumaric Acid | S-217622 | Approved | Shionogi & Co Ltd, Hokkaido University | Xocova | Japan | Coronavirus Disease 2019 (COVID-19) | Shionogi & Co Ltd | 2022-11-22 | Coronavirus Disease 2019 (COVID-19); Kidney Diseases; Post-Acute COVID-19 Syndrome; Coronaviridae Infections; Hepatic Insufficiency | Details |
Nirmatrelvir/Ritonavir | Approved | Pfizer Inc | Paxlovid | EU | Coronavirus Disease 2019 (COVID-19) | Pfizer Europe Ma Eeig | 2022-01-28 | Coronavirus Disease 2019 (COVID-19); Post-Acute COVID-19 Syndrome; Coronaviridae Infections | Details | |
Atilotrelvir/Ritonavir | Approved | Fujian Guangsheng Zhonglin Biotechnology Co Ltd | 泰中定 | Mainland China | Coronavirus Disease 2019 (COVID-19) | Fujian Guangsheng Zhonglin Biotechnology Co Ltd | 2023-11-23 | Coronavirus Disease 2019 (COVID-19) | Details | |
Simnotrelvir | SIM-0417; SSD-8432; VV-934 | Approved | Jiangsu Simcere Pharmaceutical Co Ltd | Mainland China | Coronavirus Disease 2019 (COVID-19) | Jiangsu Simcere Pharmaceutical Co Ltd | 2023-01-28 | Coronavirus Disease 2019 (COVID-19) | Details | |
Leritrelvir | RAY-1216; [14C]RAY1216; [14C]-RAY-1216 | Approved | Guangdong Raynovent Biotech Co Ltd | 乐睿灵 | Mainland China | Coronavirus Disease 2019 (COVID-19) | Guangdong Raynovent Biotech Co Ltd | 2023-03-23 | Coronavirus Disease 2019 (COVID-19); Acute Kidney Injury; Hepatic Insufficiency | Details |
Simnotrelvir/Ritonavir | SIM-0417/Ritonavir; SSD-8432 / Ritonavir; SIM-0417 / Ritonavir; VV934 / Ritonavir | Approved | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Jiangsu Simcere Pharmaceutical Co Ltd, Wuhan Institute Of Virology, Chinese Academy Of Sciences | 先诺欣 | Mainland China | Coronavirus Disease 2019 (COVID-19) | Jiangsu Simcere Pharmaceutical Co Ltd | 2023-01-28 | Coronavirus Disease 2019 (COVID-19); Kidney Diseases; Hepatic Insufficiency | Details |
Ensitrelvir Fumaric Acid | S-217622 | Approved | Shionogi & Co Ltd, Hokkaido University | Xocova | Japan | Coronavirus Disease 2019 (COVID-19) | Shionogi & Co Ltd | 2022-11-22 | Coronavirus Disease 2019 (COVID-19); Kidney Diseases; Post-Acute COVID-19 Syndrome; Coronaviridae Infections; Hepatic Insufficiency | Details |
Nirmatrelvir/Ritonavir | Approved | Pfizer Inc | Paxlovid | EU | Coronavirus Disease 2019 (COVID-19) | Pfizer Europe Ma Eeig | 2022-01-28 | Coronavirus Disease 2019 (COVID-19); Post-Acute COVID-19 Syndrome; Coronaviridae Infections | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Ebselen | SPI-1005; SPI-3005; PZ-51; DR-3305 | Phase 3 Clinical | Sound Pharmaceuticals Inc, Daiichi Sankyo Co Ltd | Tinnitus; Head and Neck Neoplasms; Diabetes Mellitus, Type 1; Ototoxicity; Diabetes Mellitus, Type 2; Coronavirus Disease 2019 (COVID-19); Small Cell Lung Carcinoma; Bipolar Disorder; Neoplasms; Hearing Loss; Coronavirus Infections; Depressive Disorder, Treatment-Resistant; Lung Neoplasms; Hearing Loss, Noise-Induced; Meniere Disease; Mental Disorders | Details |
Olgotrelvir | STI1558; STI-1558 | Phase 3 Clinical | Texas A&M University | Coronavirus Disease 2019 (COVID-19) | Details |
S-892216 | S-892216 | Phase 3 Clinical | Shionogi & Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
Mprosevir | WPV-01 | Phase 3 Clinical | Westlake University | Coronavirus Disease 2019 (COVID-19) | Details |
QLS-1128 | QLS-1128 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
MIR-19 | MIR-19 | Phase 3 Clinical | St. Petersburg Scientific Research Institute of Vaccines and Sera | Coronavirus Disease 2019 (COVID-19) | Details |
Bofutrelvir | FB-2001; DC-402234 | Phase 3 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Frontier Biotechnologies Inc | Coronavirus Disease 2019 (COVID-19) | Details |
Pomotrelvir | PBI-0451 | Phase 2 Clinical | Pardes Biosciences Inc | Coronavirus Disease 2019 (COVID-19) | Details |
SHEN-211 | SHEN-211; SHEN211 | Phase 2 Clinical | Hubei JKT BioPharma Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
HS-10517 | HS-10517; HS10517 | Phase 2 Clinical | Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
EDP-235 | EDP-235 | Phase 2 Clinical | Enanta Pharmaceuticals Inc | Coronavirus Disease 2019 (COVID-19) | Details |
Tollovir | Phase 2 Clinical | Todos Medical Ltd | Coronavirus Disease 2019 (COVID-19) | Details | |
Pentarlandir | SNB-01; SNB-011 | Phase 2 Clinical | Syneurx International (Taiwan) Corp | Coronavirus Disease 2019 (COVID-19) | Details |
Nirmatrelvir | PF-07321332 | Phase 2 Clinical | Pfizer As | Coronavirus Disease 2019 (COVID-19); Post-Acute COVID-19 Syndrome; Hepatic Insufficiency | Details |
CDI-988 | CDI988 | Phase 1 Clinical | Cocrystal Pharma Inc | Coronavirus Disease 2019 (COVID-19) | Details |
CMX-990 | CMX-990; CMX990 | Phase 1 Clinical | The Scripps Research Institute Inc | Coronavirus Disease 2019 (COVID-19) | Details |
WPV-02 | WPV-02; WPV02 | Phase 1 Clinical | Westlake Pharmaceuticals (Hangzhou) Co Ltd | Virus Diseases | Details |
ISM-3312 | ISM-3312 | Phase 1 Clinical | Insilico Medicine Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
SYH-2055 | SYH-2055 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
Atilotrelvir | GST-HG171 | Phase 1 Clinical | Fujian Guangsheng Zhonglin Biotechnology Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
ALG-097558 | ALG-097558 | Phase 1 Clinical | Rega Institute, Ku Leuven, Aligos Therapeutics Inc | Coronavirus Disease 2019 (COVID-19) | Details |
ASC11 | ASC-11 | Phase 1 Clinical | Ascletis Pharma Inc | Coronavirus Disease 2019 (COVID-19) | Details |
Lufotrelvir | PF-07304814 | Phase 1 Clinical | Pfizer Inc | Coronavirus Disease 2019 (COVID-19); Virus Diseases | Details |
Travatrelvir | TRX-01 | Clinical | Traws Pharma Inc | Coronavirus Disease 2019 (COVID-19) | Details |
GS221 | GS-221; GS221 | Clinical | Grand Pharmaceutical (China) Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
Ebselen | SPI-1005; SPI-3005; PZ-51; DR-3305 | Phase 3 Clinical | Sound Pharmaceuticals Inc, Daiichi Sankyo Co Ltd | Tinnitus; Head and Neck Neoplasms; Diabetes Mellitus, Type 1; Ototoxicity; Diabetes Mellitus, Type 2; Coronavirus Disease 2019 (COVID-19); Small Cell Lung Carcinoma; Bipolar Disorder; Neoplasms; Hearing Loss; Coronavirus Infections; Depressive Disorder, Treatment-Resistant; Lung Neoplasms; Hearing Loss, Noise-Induced; Meniere Disease; Mental Disorders | Details |
Olgotrelvir | STI1558; STI-1558 | Phase 3 Clinical | Texas A&M University | Coronavirus Disease 2019 (COVID-19) | Details |
S-892216 | S-892216 | Phase 3 Clinical | Shionogi & Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
Mprosevir | WPV-01 | Phase 3 Clinical | Westlake University | Coronavirus Disease 2019 (COVID-19) | Details |
QLS-1128 | QLS-1128 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
MIR-19 | MIR-19 | Phase 3 Clinical | St. Petersburg Scientific Research Institute of Vaccines and Sera | Coronavirus Disease 2019 (COVID-19) | Details |
Bofutrelvir | FB-2001; DC-402234 | Phase 3 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Frontier Biotechnologies Inc | Coronavirus Disease 2019 (COVID-19) | Details |
Pomotrelvir | PBI-0451 | Phase 2 Clinical | Pardes Biosciences Inc | Coronavirus Disease 2019 (COVID-19) | Details |
SHEN-211 | SHEN-211; SHEN211 | Phase 2 Clinical | Hubei JKT BioPharma Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
HS-10517 | HS-10517; HS10517 | Phase 2 Clinical | Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
EDP-235 | EDP-235 | Phase 2 Clinical | Enanta Pharmaceuticals Inc | Coronavirus Disease 2019 (COVID-19) | Details |
Tollovir | Phase 2 Clinical | Todos Medical Ltd | Coronavirus Disease 2019 (COVID-19) | Details | |
Pentarlandir | SNB-01; SNB-011 | Phase 2 Clinical | Syneurx International (Taiwan) Corp | Coronavirus Disease 2019 (COVID-19) | Details |
Nirmatrelvir | PF-07321332 | Phase 2 Clinical | Pfizer As | Coronavirus Disease 2019 (COVID-19); Post-Acute COVID-19 Syndrome; Hepatic Insufficiency | Details |
CDI-988 | CDI988 | Phase 1 Clinical | Cocrystal Pharma Inc | Coronavirus Disease 2019 (COVID-19) | Details |
CMX-990 | CMX-990; CMX990 | Phase 1 Clinical | The Scripps Research Institute Inc | Coronavirus Disease 2019 (COVID-19) | Details |
WPV-02 | WPV-02; WPV02 | Phase 1 Clinical | Westlake Pharmaceuticals (Hangzhou) Co Ltd | Virus Diseases | Details |
ISM-3312 | ISM-3312 | Phase 1 Clinical | Insilico Medicine Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
SYH-2055 | SYH-2055 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
Atilotrelvir | GST-HG171 | Phase 1 Clinical | Fujian Guangsheng Zhonglin Biotechnology Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
ALG-097558 | ALG-097558 | Phase 1 Clinical | Rega Institute, Ku Leuven, Aligos Therapeutics Inc | Coronavirus Disease 2019 (COVID-19) | Details |
ASC11 | ASC-11 | Phase 1 Clinical | Ascletis Pharma Inc | Coronavirus Disease 2019 (COVID-19) | Details |
Lufotrelvir | PF-07304814 | Phase 1 Clinical | Pfizer Inc | Coronavirus Disease 2019 (COVID-19); Virus Diseases | Details |
Travatrelvir | TRX-01 | Clinical | Traws Pharma Inc | Coronavirus Disease 2019 (COVID-19) | Details |
GS221 | GS-221; GS221 | Clinical | Grand Pharmaceutical (China) Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
This web search service is supported by Google Inc.